Navigation Links
Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants
Date:2/26/2008

d revenue growth expertise, Alimera Sciences' products are focused on improving the delivery of therapeutic agents to enhance patients' lives and strengthen physicians' ability to manage ocular conditions. Alimera has recently completed enrollment of its 956-patient phase III clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for the treatment of diabetic macular edema. For more information, please visit http://www.alimerasciences.com.

About Emory University

Emory University is one of the nation's leading private research universities and a member of the Association of American Universities. Known for its demanding academics, outstanding undergraduate college of arts and sciences, highly ranked professional schools, and state-of-the-art research facilities, Emory is ranked as one of the country's top 20 national universities by U.S. News & World Report. In addition to its nine schools, the university encompasses The Carter Center, Yerkes National Primate Research Center and Emory Healthcare, Georgia's largest and most comprehensive health care system. Emory's technology transfer success, in the life sciences area alone, includes eight licensed products with market approval for the treatment of HIV and an additional nine potential therapeutics in various stages of clinical development by its licensees.


'/>"/>
SOURCE Alimera Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Caliper Life Sciences Reports Fourth Quarter and Full Year 2007 Results
2. Derma Sciences Announces Several Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming APWCA Conference
3. Accipiter Life Sciences Announces Nomination of Three Independent Director Candidates for Election to the Penwest Board at the 2008 Annual Meeting
4. Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S.
5. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
6. Pennsylvania Gov. Rendell: $10 Million Partnership With Harrisburg Venture Capital Firm Boosts PAs Life Sciences Industry
7. Summary Notice of Proposed Settlement and Settlement Hearing in Re Martek Biosciences Corp., Securities Litigation
8. Edwards Lifesciences Reports Strong Fourth Quarter Sales
9. 7th Annual Wiley Prize in Biomedical Sciences Awarded to Dr. Richard P. Lifton
10. Advanced Life Sciences to Participate in Antibiotics Expert Panel at the 10th Annual BIO CEO & Investor Conference
11. Caliper Life Sciences Ships 500th IVIS Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...SHINGTON, May 16 /PRNewswire-USNewswire/ -- More t...ns in the Greater Portland, Oregon and,Vancouver, ...tract as,Teamsters., "The Teamsters are pleased t...ract that gives them job protection and a secure r...t Jim Hoffa., The workers, both full-time and par...
(Date:5/16/2008)...Phase III clinical trial has found that the experi...icantly delays cancer progression in patients with...ed on other treatments. The study was led by Robe...Sloan-Kettering Cancer Center (MSKCC), who will pr... of the American Society for Clinical Oncology. ,...
(Date:5/16/2008)...dicine is in a precipitous decline, David C. Dale,...ysicians (ACP), today joined with leading represe...l for comprehensive reforms to attract, recruit an... physicians. , During a panel discussion of the...ale and other panelists spoke about the challenges...
(Date:5/16/2008)...swire/- "Huh, what did you,say?" is a phrase being...ildren. More than 30 million Americans, that is 1 ...d the numbers are growing at a dramatic rate.,Thir...e form of hearing,loss. An effort to bring more at...t led Kathlyn Maguire, who has profound hearing lo...
Breaking Medicine News(10 mins):Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 2Health News:Huh, What Did You Say?: May is 'Better Hearing and Speech Month' 3
...edy for many ills, and AIDS/HIV is also one of the...who are educated till the secondary levels show a/..., rather than jumping at the first opportunity. Th...mportance of protected sex, according to a novel r...
... all those women on weight loss programmes, aspiri... sure that cellulite is extremely obstinate// and ...ose weight. New research has indicated that when...es the cellulite actually makes the skin look wors...
...cer cells that share many characteristics with nor...ancers by promoting tumor blood vessel// formation...ncers, a research team reported in the August 15th...emy Rich, M.D., associate professor at the Preston...
...he Saint Louis University published his findings o...nthrax vaccine, this month//. According to peer-re...ine could elicit the kind of immune response docto... first human testing, the vaccine was given to 100...
Other Medicine News:Health News:Cancer Stem Cells Could Hold Key to Brain Tumor Therapy 2
(Date:5/16/2008)... -- for Lung Cancer Diagnosis and, Identification ... Primary (CUP), ...igh Sensitivity and, Specificity and Could Revol...s of microRNA Signature to Identify Tissue Origin ... Specificity of 99%, REHOVOT, Israel and JERSEY C...
(Date:5/15/2008)...wswire/ -- Eisai Corporation of North,America anno...tracts about,compounds in the company,s oncology p...y research have been accepted for presentation at ... Clinical Oncology (ASCO),taking place in Chicago...abstracts on Eisai marketed products and,investiga...
(Date:5/15/2008)...ed Acceptable Tolerability Profile, wi...DCLIFF LAKE, N.J., May 15 /- The inve...te (E7389) demonstrated activity in a,heavily pret...r metastatic,breast cancer, according to results o...y also suggests that eribulin mesylate has a manag...
(Date:5/15/2008)...ire-FirstCall/ -- Sanofi-aventis,(EURONEXT: SAN an...e,landmark ATHENA study showed Multaq(R) (dronedar...ients with atrial fibrillation or atrial flutter,...ons or death from any,cause by a statistically sig...mary endpoint. The ATHENA results will be presente...
Breaking Medicine Technology:Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7European Union forests expanding absorbing carbon at surprisingly high rate 3A study 1383 1European Union forests expanding absorbing carbon at surprisingly high rate 3A study 1383 2European Union forests expanding absorbing carbon at surprisingly high rate 3A study 1383 3McGill researchers link enzyme to breast cancer malignancy 7212 1McGill researchers link enzyme to breast cancer malignancy 7212 2Workshops on biotechnology and water for science journalists 1379 1MDS Nordion Divests Non Strategic Product Lines 7205 1MDS Nordion Divests Non Strategic Product Lines 7205 2
...eostasis Effects in,Normal and Diabetic Rats --, C... a 14-day,Phase IIa study of the safety profile o...apagliflozin, a selective inhibitor of,the Sodium-...r,concomitantly with metformin in subjects with Ty...events and no serious adverse,events were reported...
...ovagali Pharma, an,emerging pharmaceutical company...sults of its pivotal phase III clinical trial,posi...Vekacia(R) in,children suffering from Vernal Kerat...ss of ophthalmology (AACO) held from June 20,to 25...rm of chronic allergic conjunctivitis,characterize...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
... are offered as 1-piece or modular, in regular or ... customized with handles of choice and other optio...any standard patterns are available from Mediflex ... times. , Please Note: Individual instrument com...
... are offered as 1-piece or modular, in regular or ... customized with handles of choice and other optio...any standard patterns are available from Mediflex ... times. , Please Note: Individual instrument com...
...struments incorporate a layered design unique in t...tored to prevent stray electrosurgical burns along...failure or capacitive coupling; a well-documented ...nto all AEM Instruments provides a neutral return ...
...ments incorporate a layered design unique in the i...d to prevent stray electrosurgical burns along the...ure or capacitive coupling; a well-documented pati...all AEM Instruments provides a neutral return path...
Medicine Products: